West Pharmaceutical Services (NYSE:WST) Shares Gap Down - Should You Sell?

Key Points

• Shares gapped down: WST opened at $240.39 after a $248.06 close and was last near $235.98 on heavy volume, trading below its 50‑ and 200‑day moving averages (~$253 and $262).
• Analyst sentiment is positive: The consensus rating is "Buy" with an average price target of $314.56 and recent analyst targets roughly in the $285–$340 range.
• Corporate fundamentals and capital returns: West beat quarterly estimates ($2.04 EPS vs. $1.83 expected; $805M revenue), set FY2026 guidance of $7.85–$8.20 EPS, announced a $1.00 billion share buyback, and pays a $0.22 quarterly dividend.

West Pharmaceutical Services, Inc. (NYSE:WST - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $248.06, but opened at $240.39. West Pharmaceutical Services shares last traded at $235.9790, with a volume of 400,985 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. UBS Group reissued a "buy" rating and issued a $340.00 price target on shares of West Pharmaceutical Services in a report on Friday, February 13th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $315.00 target price on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Evercore lowered their price target on West Pharmaceutical Services from $390.00 to $320.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 3rd. Morgan Stanley assumed coverage on West Pharmaceutical Services in a research note on Monday, December 1st. They set an "equal weight" rating and a $285.00 price target for the company. Finally, Wall Street Zen raised West Pharmaceutical Services from a "hold" rating to a "buy" rating in a report on Saturday, December 20th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $314.56.

West Pharmaceutical Services Stock Performance

The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. The company has a market cap of $16.80 billion, a PE ratio of 34.36, a PEG ratio of 2.61 and a beta of 1.17. The business's 50-day moving average is $253.16 and its 200 day moving average is $262.29.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm had revenue of $805.00 million for the quarter, compared to analysts' expectations of $795.70 million. During the same period last year, the firm earned $1.82 earnings per share. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services's payout ratio is presently 12.96%.

West Pharmaceutical Services announced that its board has approved a share buyback plan on Tuesday, February 17th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its stock is undervalued.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of West Pharmaceutical Services by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,704,948 shares of the medical instruments supplier's stock worth $2,545,899,000 after purchasing an additional 388,144 shares during the last quarter. State Street Corp raised its position in West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier's stock valued at $715,884,000 after purchasing an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in West Pharmaceutical Services by 2.9% in the 4th quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier's stock worth $784,259,000 after buying an additional 79,481 shares during the period. Geode Capital Management LLC lifted its holdings in West Pharmaceutical Services by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier's stock worth $512,250,000 after buying an additional 11,962 shares during the period. Finally, Generation Investment Management LLP grew its position in shares of West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier's stock worth $429,733,000 after buying an additional 585,855 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company's stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.